Related Experiment Videos
Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression
1Department of Cardiology, Castle Hill Hospital, University of Hull, Kingston upon Hull, UK.
Insights
Ischaemic heart disease is a leading cause of heart failure, impacting treatment effectiveness. Ongoing trials aim to establish evidence-based guidelines for managing coronary artery disease in heart failure patients.
Area of Science:
- Cardiology
- Heart Failure Research
- Ischaemic Heart Disease Management
Background:
- Ischaemic heart disease is the primary cause of heart failure in industrialized nations.
- Prognosis for heart failure patients with ischaemic heart disease is often poorer compared to other etiologies.
- The presence of ischaemic heart disease influences treatment efficacy and selection.
Purpose of the Study:
- To review the current understanding of ischaemic heart disease's impact on heart failure.
- To highlight the need for evidence-based management strategies for coronary artery disease in heart failure patients.
- To discuss ongoing research addressing therapeutic uncertainties.
Main Methods:
- Literature review and synthesis of existing evidence regarding ischaemic heart disease and heart failure.
- Analysis of treatment efficacy for various agents in patients with and without ischaemic heart disease.
- Identification of areas requiring further investigation through randomized controlled trials.
Main Results:
- Certain medications (e.g., digoxin, amlodipine) show reduced efficacy in ischaemic heart failure.
- Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers demonstrate comparable or enhanced effectiveness.
- Uncertainty exists regarding the use of anticoagulants, anti-platelets, and statins, alongside revascularization procedures.
Conclusions:
- Management of coronary artery disease in heart failure patients requires robust evidence.
- Randomized controlled trials are crucial for resolving therapeutic dilemmas.
- Upcoming trials are expected to provide a strong evidence base for clinical practice.
Abstract:
Ischaemic heart disease is the most common underlying cause of heart failure in industrialised countries. Its manifestations are protean with myocardial infarction being only one important facet. The prognosis of patients with heart failure due to ischaemic heart disease also appears to be worse than that associated with many other aetiologies. The presence of ischaemic heart disease may influence both the efficacy and choice of treatment. Agents such as digoxin and amlodipine appear less effective in patients with ischaemic heart disease while ACE inhibitors and beta-blockers appear as or more effective in patients with ischaemic heart disease. Many have expressed an opinion about how coronary disease should be managed in the patient with heart failure supported by little or no evidence. There are major theoretical and practical concerns about the use of anti-coagulant, anti-platelet and statin therapy in patients with heart failure as well as major theoretical benefits. Only randomised controlled trials will resolve these issues. The same may be said of revascularisation. Fortunately trials addressing all these areas are under way. This should put the management of coronary disease in patients with heart failure on a firm evidence-based footing.